בינוקריט 10000 יחבל  1 מל Israel - hebreo - Ministry of Health

בינוקריט 10000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 10000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 20000 יחבל  0.5 מל Israel - hebreo - Ministry of Health

בינוקריט 20000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 3000 יחבל  0.3 מל Israel - hebreo - Ministry of Health

בינוקריט 3000 יחבל 0.3 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 40000 יחבל  1 מל Israel - hebreo - Ministry of Health

בינוקריט 40000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

צפוויט פורטה תרחיף Israel - hebreo - Ministry of Health

צפוויט פורטה תרחיף

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - אבקה להכנת תרחיף - cefalexin as monohydrate 250 mg / 5 ml - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

צפוויט 250 Israel - hebreo - Ministry of Health

צפוויט 250

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 250 mg - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

צפוויט פורטה 500 Israel - hebreo - Ministry of Health

צפוויט פורטה 500

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 500 mg - cefalexin - cefalexin - treatment of infections caused by cephalexin susceptible microorganisms.

יירבוי 5 מגמל Israel - hebreo - Ministry of Health

יירבוי 5 מגמל

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

אקסג'יבה Israel - hebreo - Ministry of Health

אקסג'יבה

amgen europe b.v. - denosumab - תמיסה להזרקה - denosumab 120 mg / 1.7 ml - denosumab - denosumab - prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.